Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;8(11):692.
doi: 10.21037/atm-20-3790.

A single-center 14-year follow-up study of the BalMedic® bovine pericardial bioprosthetic valve

Minghao Lin  1 , Naiyan Gan  1 , Jun Chen  1 , Kai Lv  1 , Shengfu Han  1 , Huazhen Huang  1
Affiliations

A single-center 14-year follow-up study of the BalMedic® bovine pericardial bioprosthetic valve

Minghao Lin et al. Ann Transl Med. 2020 Jun.

Abstract

Background: The causes of valvular disease in China are complex, with a broad age distribution. For patients with early mechanical valve replacement, the quality of life is affected by postoperative anticoagulation-related complications. Since 2005, we have used bioprosthetic valves to provide more options for patients. In this study, we retrospectively analyzed the 14-year follow-up data of patients undergoing BalMedic bovine pericardial bioprosthetic valve replacement (manufacturer: Beijing Balance Medical Tech Co., Ltd.) to evaluate its intermediate- to long-term clinical effectiveness.

Methods: From 2005 to 2014, 336 BalMedic pericardial bioprosthesis valves were implanted in 299 patients (mean age 53.5 years, 59.86% female) at The First People's Hospital of Yulin. Among followed up 290 discharged patients, 284 underwent aortic valve replacement and mitral valve replacement (AVR group, MVR group) for further grouping analysis, 6 underwent tricuspid valve replacement (TVR). The mean follow-up was 7.7±2.5 years (5 to 14), for a total of 2,196 valve-years, 98.28% of the patients completed follow-up.

Results: The perioperative mortality was 3% (9/299). After discharge, 68 patients (23.4%, 68/290) died, and 36 (12.4% 36/290) underwent the second valve replacement. The overall 5- and 10-year survival rates were 89.95% and 72.53%, respectively. For patients undergoing AVR alone, the overall 10-year survival rates were 80.64%, the reoperation-free rates were 92.94%, and the SVD-free rates were 90.95%. For patients undergoing MVR and double valve replacement (DVR group), the 10-year survival rates were 67.21% and 82.90%, the reoperation-free rates were 72.26% and 73.33%, the SVD-free rates were 58.90% and 53.80%, respectively. Subgroup analysis by age showed no significant intergroup difference in overall survival but a significant intergroup difference in reoperation-free and SVD-free rates (P<0.05).

Conclusions: With a similar 10-year overall survival rate as its foreign counterparts, BalMedic bovine pericardial bioprosthesis is reliable choice for both aortic valve and mitral valve. In patients undergoing AVR, the BalMedic valve is superior to the similar foreign counterparts in overall survival, reoperation-free survival, and SVD-free rates. While in MVR or DVR, Chinese patients are younger because of different etiology, postoperative outcomes show non-inferior to those from the foreign counterparts.

Keywords: BalMedic®; bovine pericardial bioprosthesis; intermediate- and long-term follow-up.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3790). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Kaplan-Meier overall survival curves.
Figure 2
Figure 2
Survival curves of the AVR group, the MVR group, and the DVR group. AVR, aortic valve replacement; MVR, mitral valve replacement; DVR, double valve replacement.
Figure 3
Figure 3
Survival curves of different age groups.
Figure 4
Figure 4
Kaplan-Meier curve for reoperation-free rate.
Figure 5
Figure 5
Kaplan-Meier curve for reoperation-free rate in the AVR group, the MVR group, and the DVR group. AVR, aortic valve replacement; MVR, mitral valve replacement; DVR, double valve replacement.
Figure 6
Figure 6
Kaplan-Meier curve for reoperation-free rate in different age groups.
Figure 7
Figure 7
Kaplan-Meier curve for overall SVD-free rate. SVD, structural valve damage.
Figure 8
Figure 8
Kaplan-Meier curve for SVD-free rate in the AVR group, the MVR group and the DVR group. SVD, structural valve damage; AVR, aortic valve replacement; MVR, mitral valve replacement; DVR, double valve replacement.
Figure 9
Figure 9
Kaplan-Meier curve for SVD-free rate in different age groups. SVD, structural valve damage.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sidhu P, Okane H, Ali N, et al. Mechanical or bioprosthetic valves in the elderly: a 20-year comparison. Ann Thorac Surg 2001;71:S257-60. 10.1016/S0003-4975(01)02522-X - DOI - PubMed
    1. Antoniou A, Harky A, Yap J, et al. Bioprosthetic aortic valve replacement: a telltale from the young. Ann Transl Med 2018;6:185. 10.21037/atm.2018.02.19 - DOI - PMC - PubMed
    1. Singh M, Sporn ZA, Schaff HV, et al. ACC/AHA Versus ESC Guidelines on Prosthetic Heart Valve Management: JACC Guideline Comparison. J Am Coll Cardiol 2019;73:1707-18. 10.1016/j.jacc.2019.01.038 - DOI - PubMed
    1. Han QQ, Xu ZY, Zhang BR, et al. Primary triple valve surgery for advanced rheumatic heart disease in Mainland China: a single-center experience with 871 clinical cases. Eur J Cardiothorac Surg 2007;31:845-50. 10.1016/j.ejcts.2007.02.005 - DOI - PubMed
    1. Wang Y, Chen S, Hu XJ, et al. Mid- to Long-term Clinical Outcomes of Hancock II Bioprosthesis in Chinese Population. Chin Med J (Engl) 2015;128:3317-23. 10.4103/0366-6999.171424 - DOI - PMC - PubMed